Low P/E Alert! These 3 Undervalued Stocks Are Poised to Surge Over 90%

Using the TipRanks Stock Screener Tool, we identified three companies that have low Price-to-Earnings (P/E) ratios and hold a “Strong Buy” consensus rating. Each stock also presents an impressive >90% upside potential within the next year, making them compelling investment choices.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Why Low P/E Stocks?

Low P/E stocks trade at a discount to their earnings, letting you buy more profit per dollar invested. This inherent margin of safety buffers against market dips and losses. While some chase high P/E names for rapid growth, history shows low P/E picks often yield better long-term returns with lower risk. They also tend to offer generous dividends, hail from established companies with steady growth, and exhibit less volatility.

Bit Digital

• P/E Ratio: 4.2x (83% below sector median of 23.12x)
• Average Bit Digital Price Target: $4.75 (191% upside)

Bit Digital operates as a digital asset platform with a focus on Ethereum (ETH-USD). It runs one of the world’s largest institutional Ethereum-staking infrastructures, where staking involves using digital coins to help run and secure a blockchain network in exchange for rewards. This focus aligns with Ethereum’s ongoing upgrades and DeFi growth, potentially providing a more scalable, income-oriented model. As of January 31, 2026, the company held approximately 155,239.4 ETH (ETH-USD), valued at about $380.2 million.

Geo Group

• P/E Ratio: 8x (63% below sector median of 21.62x)
• Average Geo Group Price Target: $30.33 (107% upside)

The Geo Group operates private prisons, immigration detention centers, re-entry programs, and electronic monitoring services via long-term government contracts in the U.S. and abroad. GEO manages facilities housing tens of thousands across 100 sites globally, earning steady revenue from agencies paying for incarceration, supervision, and tech-based monitoring like ankle bracelets.

Cormedix

• P/E Ratio: 3.5x (82% below sector median of 18.89x)
• Average Cormedix Price Target: $13.67 (90.7% upside)

CorMedix is a biopharmaceutical company focused on developing and commercializing therapies to prevent and treat infectious and inflammatory diseases. The company projects $300-$320 million in 2026 revenue, including $150-$170 million from its lead product DefenCath, alongside anticipated adjusted EBITDA of $100-$125 million, supported by high gross margins around 94%. Pipeline advancements include Phase 3 data for REZZAYO expected in Q2 2026 and ongoing trials for DefenCath in TPN patients, targeting rising demand from aging populations and chronic diseases.

Copyright © 2026, TipRanks. All rights reserved.